- not yet recruitingNA
Resistance Exercise, IL-7 and Immune Phenotypes in Prostate Cancer
This study looks at whether strength training can help men with prostate cancer on hormone therapy. It investigates if exercise can prevent muscle loss, boost immune cells, and improve quality of life, which often suffer during treatment.
United Kingdom - completed
Using software to measure bone disease on imaging for patients with prostate cancer
This study looks at using whole-body MRI scans and smart computer software for men with advanced prostate cancer that has spread to the bones. Researchers want to see if this technology can show whether a new treatment is working much faster than regular CT or bone scans.
United Kingdom - recruiting
Using targeted radiotherapy to postpone the need to change treatment in men diagnosed with metastatic prostate cancer
This UK trial looks at whether a precise type of targeted radiotherapy (SBRT) can help men with advanced prostate cancer. Researchers want to see if treating small cancer spots delays the disease from worsening, helping patients stay on their current hormone treatment longer and maintain a good quality of life.
United Kingdom · England - completedPhase I/II
Saracatinib (AZD0530) and docetaxel in metastatic castrate-refactory prostate cancer
This clinical trial tests a new drug called saracatinib alongside standard docetaxel chemotherapy. It is for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. Researchers want to find out if this combination is safe and helps slow cancer growth.
United Kingdom · Scotland - completedPhase IV
A trial looking at metformin for early prostate cancer patients undergoing surgery
This UK clinical trial is testing whether metformin, a common diabetes medicine, can help treat prostate cancer. Men waiting for surgery to remove their prostate take either metformin or dummy tablets for several weeks before their operation. Researchers then study the removed tissue to see how the drug affects cancer cells.
United Kingdom · England · Wales - completed
Radium-223: evaluation of activity and surrogate response
This trial looks at a treatment called Radium-223 for men with prostate cancer that has spread to the bones. Researchers are comparing two different doses to see which works best. They also want to find out if simple blood tests can show how well the treatment is fighting the cancer.
United Kingdom · England - authorisedTherapeutic use (Phase IV)
ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment
This study looks at a specialised scan called a PSMA PET scan. Researchers want to find out how well this scan detects if prostate cancer has returned one year after focused ultrasound treatment (HIFU). The scan uses a gentle tracking dye to help doctors spot any lingering cancer cells early.
France - completed
Exercise training for men with prostate cancer on hormone therapy
The STAMINA study looks at whether guided exercise can help men with prostate cancer manage the side effects of hormone therapy. Participants are randomly chosen either to join a 12-month supervised exercise programme with trained fitness coaches or to receive standard NHS care with general exercise advice.
United Kingdom · England - completed
Study of fewer, larger doses of radiotherapy for men with localised prostate cancer
This study is testing whether giving prostate cancer radiotherapy in just two or five high-dose sessions works as well as the standard 20 sessions. Using a high-tech scanning machine, doctors can accurately target the prostate, hoping to cure the cancer while reducing hospital visits and protecting healthy tissue.
United Kingdom · England - authorisedHuman Pharmacology (Phase I)- First administration to humans
An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-naïve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
This early-stage study tests a new medicine called TRP-001 for men with high-risk prostate cancer who are due to have surgery. Doctors want to find a safe dose to give before an operation, and check how well it targets the cancer without causing severe side effects.
Germany - authorisedTherapeutic exploratory (Phase II)
PET-Guided Navigation with Electromagnetic Tracking during PSMA-RadioGuided Surgery: Innovative Bimodal Detection of Nodal Metastases in Prostate Cancer Patients
This trial looks at a new surgical navigation tool for prostate cancer. Surgeons use a harmless radioactive tracer and magnetic tracking to find and remove cancer that has spread to lymph nodes. The study checks whether this method lowers prostate-specific antigen (PSA) levels six weeks after surgery.
Italy - authorisedTherapeutic exploratory (Phase II)
A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer
This study tests a targeted radiation treatment called 177Lu-PSMA for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. Doctors want to see if adapting the dose to each patient safely slows down the cancer, lowers PSA levels, and eases pain.
Sweden - recruitingTherapeutic exploratory (Phase II)
Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
This study is looking at a new treatment called Lutetium-177-PSMA for men with prostate cancer that hasn't spread widely and is sensitive to hormone therapy. It aims to see if this treatment can slow down the cancer's growth.
Cyprus · Netherlands - recruitingTherapeutic confirmatory (Phase III)
Prospective Study of Added Value of Florastamin (18F) PET/CT in Localisation of Clinically Significant Prostate Cancer in Patients with PI- Report of Multi-Parametric MRI, Elevated Serum PSA Levels and/or PSA Density and with Clinical Suspicion of Prostate Cancer
This study is looking at a new imaging test, called Prostavue, for men who might have prostate cancer. It wants to see how well Prostavue can find prostate cancer and help doctors decide on the best treatment plan.
Austria - recruitingTherapeutic use (Phase IV)
Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational pharmacological care of patients with prostate cancer
This study looks at how a prostate cancer drug, enzalutamide, might affect other medicines like morphine (for pain) and edoxaban (a blood thinner). The aim is to make sure patients get the best and safest care when taking these drugs together.
Netherlands - recruitingTherapeutic exploratory (Phase II)
Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer
This study looks at a special type of scan called a PET-PSMA scan to see how well it finds cancer in lymph nodes for men with prostate cancer. It helps doctors decide the best treatment, especially before surgery.
France - recruitingPhase I and Phase II (Integrated)- First administration to humans
DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.
This study looks at a new way to treat prostate cancer that has spread to the bones. It combines two types of radiation treatment, Lutetium-177 PSMA and Radium-223, given one after the other. We want to see if this treatment is safe and practical for men after their initial cancer treatment.
Netherlands - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
This study is looking at a special scan called a PET/CT with copper-64 PSMA. It aims to see how well this scan can find prostate cancer that has spread to nearby lymph nodes in men about to have surgery. This could help doctors better understand the cancer's stage.
France · Spain · Italy - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 80 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects under fasting condition.
This study is comparing two versions of a prostate cancer medicine called enzalutamide in healthy men. It wants to see if a new generic version works the same way in the body as the original one, to make sure it's just as effective.
Romania - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 160 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects under fasting condition.
This study is comparing a new version of the prostate cancer drug Enzalutamide with the original one. It's looking at how well healthy men absorb the new drug to make sure it works the same way.
Romania - completedNot Applicable
Examining the impacts of pathologists using the assistance of computer technology (artificial intelligence software) on the diagnosis of prostate cancer biopsies
This study looks at using artificial intelligence (AI) computer software to help NHS doctors diagnose prostate cancer. The AI highlights suspicious areas on biopsy tissue samples. Specialist doctors still make all final decisions. The goal is to make diagnoses faster, more consistent, and more accurate for future prostate cancer care.
United Kingdom · England - recruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
United States · Argentina · Australia - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - recruitingPHASE3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
This study is looking at a new treatment called AAA817, combined with standard prostate cancer drugs, for men with advanced prostate cancer. It compares this new combination to existing treatments to see which works best at slowing the cancer's growth.
United States · Australia · Brazil - recruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
United States · Argentina · Australia - active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
United States · Argentina · Australia - recruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
United States · Argentina · Australia - active not recruitingPHASE3
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study compares two treatments for advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests if adding a new drug, capivasertib, to standard chemotherapy (docetaxel) works better than chemotherapy alone to help patients live longer and keep the cancer from growing.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
This study looks at adding a new drug, Apalutamide, to standard hormone therapy for men with prostate cancer that has spread. We want to see if this combination helps patients live longer or keeps their cancer from getting worse.
United States · Argentina · Australia - recruiting
Partial prostate Ablation versus Radical Treatment (PART): Comparing partial ablation of the prostate to treatment or removal of the whole prostate in men with localised cancer of one side of the prostate only
The PART trial compares two treatments for prostate cancer that has not spread. It tests whether treating only the area containing cancer (partial ablation) works as well as treating or removing the whole prostate (radical treatment), while causing fewer side effects like erection or bladder problems.
United Kingdom · England · Scotland - completed
CHRONOS: Comparative health research outcomes of novel surgery in prostate cancer
The CHRONOS trial explores targeted treatments for prostate cancer, known as focal therapy. By using heat or freezing to destroy only the cancer cells rather than the whole prostate gland, doctors hope to control the cancer just as well as standard surgery or radiotherapy, but with fewer long-term side effects.
United Kingdom · England - recruiting
Aiming to understand how the primary tumour in the prostate, and the treatment of this, can affect secondary tumours at other sites
This study looks at how treating the main prostate cancer tumour can affect any cancer that has spread. We want to find better ways to treat advanced prostate cancer and stop it from becoming resistant to medicines.
United Kingdom · England - recruiting
A clinical trial to find out if using the findings from PSMA PET scans to escalate treatment can improve cancer control in patients with high-risk prostate cancer
This study looks at new scans (PSMA PET-CT) for men with high-risk prostate cancer. We want to see if using these scans to guide treatment can help control the cancer better than standard scans. It could improve future care for prostate cancer patients.
United Kingdom - recruiting
Trial of Randomised Approaches for National Screening FOR Men (TRANSFORM)
The TRANSFORM study is looking for the best way to screen men for prostate cancer. Since there's no national screening programme yet, this study aims to find a safe and effective way to detect prostate cancer early, improving treatment chances and saving lives across the UK.
United Kingdom · England - recruitingPhase I
A study of JNJ-78278343 in combination with JNJ-95298177 for treatment of prostate cancer
This study is testing two new medicines, JNJ-78278343 and JNJ-95298177, together for advanced prostate cancer. Researchers want to find the safest and most effective dose in men whose cancer has spread and is no longer responding well to standard hormone treatments.
United Kingdom · England · United States of America - completedPhase I
A study of Pasritamig (JNJ-78278343) in combination with JNJ-86974680 for treatment of prostate cancer
This study is testing two new drugs, Pasritamig and JNJ-86974680, together for men with advanced prostate cancer. Researchers want to find the safest dose and see if it helps fight the cancer. It's a very early-stage trial.
United Kingdom · England · United States of America - recruiting
A multi-centre, non-interventional study of relugolix in patients with advanced hormone-sensitive prostate cancer
This study looks at how a prostate cancer medicine called relugolix works in real life. It's for men whose doctor has already decided relugolix is the right treatment. Researchers will gather information from routine doctor visits to understand its effects, without changing participants' care.
United Kingdom · England · France - recruitingHuman Pharmacology (Phase I)- Other
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.
This study looks at how a medicine called radium-223 moves through the bodies of men with prostate cancer who are receiving this treatment. It helps doctors understand how the drug works and is processed by the body.
Austria · Italy · Lithuania - recruitingNot Applicable
SpaceOAR post-market registry study
This study looks at the long-term safety of SpaceOAR, a gel that protects men from radiation side effects during prostate cancer therapy. It collects health information from men in the UK who are already receiving SpaceOAR as part of their normal care.
United Kingdom · England - recruiting
A study to investigate using contrast-enhanced ultrasound during focal therapy for prostate cancer
This study looks at using a special ultrasound during prostate cancer treatment. It aims to help surgeons see and treat any remaining cancer straight away. This could improve how well focal therapy works for prostate cancer.
United Kingdom - recruitingPHASE3
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
This study looks at treating advanced prostate cancer with hormone tablets. Researchers want to see if a lower dose works as well as the standard dose, with fewer side effects like tiredness. It aims to improve quality of life for patients.
United Kingdom - not yet recruiting
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
This study looks at prostate cancer in UK prisons. We're checking health records to see how men in prison are diagnosed and treated for prostate cancer, and if their care is different from men outside prison. The goal is to improve health for everyone.
United Kingdom - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - active not recruitingPHASE2
Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.
This study looks at whether a special omega-3 supplement (MAG-EPA) can help men whose prostate cancer has started to come back after treatment. It aims to see if this supplement can delay the need for other treatments that might have side effects.
Canada - active not recruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
United States · Argentina · Australia - recruitingPHASE3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
This study compares a new, shorter radiation treatment for prostate cancer with the usual treatment. It checks if the new method, using high-dose radiation in fewer sessions, works as well as the standard approach which combines external radiation with tiny radioactive seeds placed inside the prostate.
United States · Canada - recruitingNA
Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.
This study compares different ways of giving radiation therapy for prostate cancer. It looks at how well a faster, more focused type of radiation, called ultra-hypofractionated therapy, works compared to a slightly longer version, both combined with internal radiation (brachytherapy), focusing on side effects.
Canada - recruitingNA
Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
This study looks at a new way to give radiation treatment for prostate cancer that has come back after surgery. It uses special scans to guide the radiation, giving more to the cancer and less to healthy areas.
Canada - active not recruitingPHASE2
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard chemotherapy (docetaxel) for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new treatment can better slow cancer growth.
Canada - active not recruitingPHASE2, PHASE3
PSMA-PET Guided Radiotherapy
This study looks at whether using a special type of scan, called PSMA-PET, before radiotherapy for prostate cancer can improve treatment results. PSMA-PET is better at finding cancer spread than standard scans, and we want to see if using this information helps cure more patients.
Canada